Analysts Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Target Price at $7.33

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $7.3333.

Several brokerages have recently weighed in on WHWK. Citigroup began coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating on the stock. Wall Street Zen cut shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Citizens Jmp began coverage on shares of Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings cut shares of Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th.

Whitehawk Therapeutics Stock Up 1.0%

WHWK opened at $4.06 on Friday. The firm has a 50 day moving average price of $4.12 and a 200-day moving average price of $3.33. Whitehawk Therapeutics has a twelve month low of $1.57 and a twelve month high of $5.49. The stock has a market capitalization of $200.77 million, a price-to-earnings ratio of -2.42 and a beta of 0.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. As a group, analysts expect that Whitehawk Therapeutics will post -1.44 earnings per share for the current year.

Insider Activity at Whitehawk Therapeutics

In related news, CEO David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock in a transaction on Monday, April 6th. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45. Following the transaction, the chief executive officer directly owned 691,154 shares in the company, valued at approximately $2,425,950.54. The trade was a 12.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $3.64, for a total value of $336,554.40. Following the transaction, the insider owned 397,106 shares in the company, valued at $1,445,465.84. This trade represents a 18.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 695,830 shares of company stock worth $2,553,026. Corporate insiders own 49.90% of the company’s stock.

Hedge Funds Weigh In On Whitehawk Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC purchased a new position in Whitehawk Therapeutics during the third quarter valued at $7,915,000. Suvretta Capital Management LLC bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at $7,030,000. Acuta Capital Partners LLC bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at $6,480,000. Avoro Capital Advisors LLC bought a new stake in shares of Whitehawk Therapeutics during the 3rd quarter valued at $5,414,000. Finally, KVP Capital Advisors LP bought a new stake in shares of Whitehawk Therapeutics during the 4th quarter valued at $5,242,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.